Unit:
Τομέας ΧειρουργικήςLibrary of the School of Health Sciences
Author:
Μητσοπούλου Μαρία
Dissertation committee:
Αν. Καθ. Βέργαδος Ιωάννης
Original Title:
Αντιμετώπιση του οιδήματος της ωχράς λόγω απόφραξης κεντρικής φλέβας αμφιβληστροειδούς με ενδοϋαλοειδική έγχυση του αντι-αγγειογενετικού παράγοντα ranibizumab (Lucentis)
Summary:
Background/Purpose: To evaluate the effect of individualized repeated
intravitreal injections of ranibizumab (Lucentis) on visual acuity (VA) and
central foveal thickness (CFT) for central retinal vein occlusion (CRVO)-
induced macular edema.
Methods: Our study was a prospective interventional case series. Twelve eyes of
12 consecutive patients diagnosed with CRVO-related macular edema (nine
perfused, three ischemic CRVO) treated with repeated (when CFT was >220 μm)
intravitreal injections of ranibizumab as a monotherapy within 3 months of
onset were evaluated. Optical coherence tomography (OCT) and fluorescein
angiography (FA) were performed monthly and every 3 months respectively.
Changes in VA (ETDRS) and CFT were analyzed using the student’s paired t-test.
Results: The mean time from diagnosis until injection was 80 days (2.7 months;
range, 63-90 days) and the follow up time was 12 months. In total, 89
injections were performed (mean 7.4). The mean CFT improved from 480±166 μm at
baseline to 230±33 μm (P<0.001) at the end of the follow-up. During the same
period, of the 12 eyes, eight (67%) demonstrated improved VA (>0.3 LogMAR
change, >15 letters), three (25%) stable VA and one (8%) worse VA as compared
to baseline. None of the nine patients with perfused CRVO were converted to
ischemic at 12 months and one of the three eyes with ischemic CRVO (33.3%)
developed iris neovascularization despite two ranibizumab injections. No ocular
or systemic side effects were noted.
Conclusion: Individualized repeated intravitreal injections of ranibizumab have
shown promising results in VA improvement and decrease in CFT in patients with
macular edema associated with CRVO. Further studies are needed in order to
elucidate the role of intravitreal lucentis in the ischemic form of CRVO and
its efficacy in preventing conversion from the perfused to the ischemic form of
the disease.
Keywords:
Lucentis, Ranibizumab, CRVO, Intravitreal injection
Number of references:
329
File:
File access is restricted only to the intranet of UoA.
document.pdf
2 MB
File access is restricted only to the intranet of UoA.
